Komori
Ono Pharmaceutical (4528) · RiskMitigated

Addressing the risk of failing to meet payment obligations by securing sufficient cash

First written in FY2017. 2 of 4 entries say "Mitigated", first in FY2018. Latest entry: FY2026.

4entries
10years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseMitigatedFY20182017: 120172018: 120182019: 020192020: 020202021: 020212022: 020222023: 020232024: 020242025: 120252026: 12026
Same theme, other companies
Liquidity and Cash Flow Management RiskA theme 266 companies write about · 262 as a headwind · 4 as a tailwind

45 other companies' latest entry also says "Mitigated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 199 companies compared. The sentences above are computed from all 199.Comparing 200 of the theme's 267 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026MitigatedAnnual report

    「At the end of the fiscal year, current assets were ¥468.3 billion, including ¥237.0 billion in cash and cash equivalents, and current liabilities were ¥163.6 billion. The company recognizes that it has sufficient liquidity to meet its needs.」

    The company explained that liquidity was sufficient, as cash and cash equivalents increased to ¥237.0 billion and repayment of the acquisition-related borrowings progressed.
  2. FY2025Changes in the liquidity structure resulting from borrowings to fund an acquisitionAnnual report

    「At the end of the current consolidated fiscal year, current assets were ¥455.1 billion, including ¥204.6 billion in cash and cash equivalents, and current liabilities were ¥148.3 billion. We recognize that necessary liquidity is sufficient. A portion of the funding required as a result of the acquisition of US-based Deciphera in June 2024 was financed through borrowings from financial institutions.」

    While the acquisition of Deciphera was financed through borrowings, the company explained that it has sufficient liquidity, including ¥204.6 billion in cash and cash equivalents.
  3. FY2018MitigatedAnnual report

    「Our group manages liquidity risk, led by the accounting department, by appropriately maintaining retained earnings and monitoring cash flow plans and actual results. However, we believe this risk is limited because we hold sufficient cash and cash equivalents and current assets and consistently secure positive cash flow from operating activities.」

    The disclosure cites maintaining retained earnings, monitoring cash flow plans and actual results, and sufficient cash and current assets as measures to address liquidity risk.
  4. FY2017First statedAnnual report

    「Our group is exposed to liquidity risk, meaning the risk that it may be unable to meet current or future payment obligations because it cannot obtain sufficient cash.」

    The disclosure identifies the liquidity risk of being unable to meet payment obligations and explains that it is managed by monitoring cash flow plans and actual results and maintaining retained earnings.
Moved together

"Strengthening Oversight Functions through the Board of Directors, Board of Corporate Auditors and Outside Officers" moved the same way as this thread, in the same document, in 2 of its 4 moves.

222222★123456
  1. ★This thread
  2. 1Strengthening Oversight Functions through the Board of Directors, Board of Corporate Auditors and Outside Officers2×
  3. 2Expansion of the development pipeline and continued launches of new drugs2×
  4. 3In-Licensing Promising New Drug Candidate Compounds and Accelerating Clinical Trials2×
  5. 4Global business expansion and international launches2×
  6. 5Drug Discovery Collaborations with Universities, Research Institutions and Biotech Ventures2×
  7. 6Expansion of Opdivo’s indications and progress in international development and sales2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Ono Pharmaceutical's next results are scheduled for 2026-10-29. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Addressing the risk of failing to meet payment obligations by securing sufficient cash | ONO PHARMACEUTICAL CO.,LTD. (4528) | Komori